Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).
Status:
Completed
Trial end date:
2024-02-16
Target enrollment:
Participant gender:
Summary
A randomised, open-label study evaluating the pharmacokinetics, safety, and tolerability of a
new once daily dose of 900mg of TETA 4HCL by comparing it against the current marketed
Cuprior® formulation (450mg trientine base, twice daily) in healthy male and female
participants.